Effect of tamoxifen on intraperitoneal N-nitroso-N-methylurea induced tumors

Cancer Letters

Volumn 100, Issue 1-2, 1996, Pages 227-234

  Martin, G ^a   Melito, G ^a   Rivera, E ^a   Levin, E ^a   Davio, C ^a   Cricco, G ^a   Andrade, N ^a   Caro, R ^a   Bergoc, R ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Mammary tumors; N nitroso N methylurea; Receptor content; Tamoxifen rats

Indexed keywords

ESTROGEN RECEPTOR; METHYLNITROSOUREA; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; CANCER INCIDENCE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DISSOCIATION CONSTANT; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT;

EID: 0030062584     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(95)04091-9     Document Type: Article

References (36)

1. Actis, A.M., Caruso, S. and Levin, E. (1994) Estrogen receptor isoform and progestin hormone dependence in a mammary tumor model. Int. J. Cancer, 58, 668-771.
2. Arafah, B.M., Finegan, H.M., Roe, J., Manni, A. and Pearson, O.N. (1982) Hormone dependence in N-nitrosomethylurea-induced rat mammary tumors. Endocrinology, 111, 584-588.
3. Beck, C.A., Weigel, M.L., Moyer, M.L., Norden, S.K. and Edwards, D.A. (1993) The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc. Natl. Acad. Sci. USA, 90, 4441-4445.
4. Brenner, S.E., Clark, G.M. and McGuire, W.L. (1988) Review: steroid receptors, cellular kinetics and lymph node status as prognostic pattern in breast cancer. Am. J. Med., 296, 59-56.
5. Brunner, N., Bronzer, D., Windelow, I., Rygard, K., Spang-Thomas, M. and Lippman, M.J. (1989) Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells growth in vivo and in nude mice. Cancer Res., 49, 1515-1520.
6. Brunner, N., Moser, C., Clarke, R. and Culler, K. (1992) IGF-I and IGF-II expression in human breast cancer xenografts: relationship to hormone independence. Breast Cancer Res. Treat., 22, 39-45.
7. Cole, M.P., Jones, C.T.A. and Todd, I.D.H. (1971) A new antioestrogenic agent in late breast cancer. An early appraisal of ICI 46,474. Br. J. Cancer, 25, 270-272.
8. Endl, K.C. and Zimniski, S.J. (1992) Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res., 52, 235-237.
9. Gibson, D.F.C., Gottardis, M.M. and Jordan, V.C. (1990) Sensitivity and insensitivity of breast cancer to tamoxifen. J. Steroid Biochem. Mol. Biol., 37, 765-770.
10. Gottardis, M.M. and Jordan, V.C. (1987) The antitumor action of keoxifene and tamoxifen in the N- nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47, 4020-4024.
11. Graham, M.L., Kret, N.L., Miller, L.A., Leslie, K.K., Gordon, D.F., Wood, W.M., Wei, L.L. and Horwitz, K.B. (1991) T4TDCD cells, genetically unstable and containing estrogen receptor mutation, are a model for the progression of breast cancer to hormone resistance. Cancer Res., 50, 6208-6217.
12. Haran, E.F., Maretzek, A.F., Goldemberg, I., Horowitz, A. and Degani, H. (1994) Tamoxifen enhances cell death in implanted MCF-7 breast cancer by inhibiting endothelium growth. Cancer Res., 54, 5511-5514..
13. Horwitz, K.B. (1993) Mechanisms of hormone resistance in breast cancer. Breast Cancer Res. Treat., 26, 119-130.
14. Jordan, V.C. (1974) Antitumoral activity of the antioestrogen ICI46,474 (tamoxifen) in the dimethylbenzo(a)anthracene (DMBA)-induced rat mammary carcinoma model. J. Steroid. Biochem., 5, 354-357.
15. Jordan, V.C. (1976) Effect of tamoxifen (ICI46,474) on initiation and growth of DMBA-induced rat carcinomata. Eur. J. Cancer, 12, 412-424.
16. Jordan, V.C., Dix, C.L. and Allen, K.E. (1979) The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Adjuvant Therapy of Cancer, pp. 19-26. Editors: S.E. Salomon and S.E. Jones. Grune and Stratton, New York.
17. Jordan, V.C., Allen, R.E. and Dix, C.L. (1980) The pharmacology of tamoxifen in laboratory animals. Cancer Treat. Rep., 64, 745-759.
18. Jordan, V.C., Lababidi, M.K. and Langan-Fahey, S. (1991) Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J. Natl. Cancer Inst., 83, 492-496.
19. Jordan, V.C. (1990) Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res. Treat., 15, 125-136.
20. Karnik, P.S., Kulkarni, S., Liv, X., Budd, G.T. and Bukowski, R.M. (1994) Estrogen receptor mutation in tamoxifen-resistant breast cancer. Cancer Res., 54, 349-353.
21. King, R.J.B., Stewart, J.F. and Mills, R.R. (1982) Quantitative comparison of estradiol and progesterone receptor on content of primary and metastatic human breast tumors in relation to response to endocrine treatment. Breast Cancer Res. Treat., 2, 339-346.
22. Love, R.R. (1990) Prospects for antiestrogen chemoprevention of breast cancer. J. Natl. Cancer Inst., 82, 18-21.
23. Maas, H., Jonat, W., Stolzenbach, G. and Trams, G. (1980) The problem of nonresponding estrogen-receptor positive patients with advanced breast cancer. Cancer, 6, 2835-2837.
24. McGuire, W.L., Chamness, G.C. and Fuqua, S.A. (1991) Estrogen receptor variant in clinical breast cancer. Mol. Endocrinol., 5, 1570-1577.
25. Osborne, C.K., Boldt, D.H., Clark, G.M. and Trent, J.M. (1983) Effects of tamoxifen on human breast cancer cell cycle kinetics. Accumulation of cells in early G1 phase. Cancer Res., 43, 3583-3585.
26. Osborne, C.K., Wiebe, U.J., McGuire, W.L., Ciocca, D. and De Gregorio, M.W. (1992) Tamoxifen and the sources of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J. Clin. Oncol., 10, 304-310.
27. Pollak, M.N., Huynth, H. and Lefebre, S.P. (1992) Tamoxifen reduces serum insulin-like growth factor I. Breast Cancer Res. Treat., 22, 91-100.
28. Porik, E.J., Nelson, K., Srinivasan, S., Powell, D.E., Keredy, D.E., De Priest, P.D., Gallion, H.H. and Nagell, Jr., J.R. (1992) Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity. Cancer Res., 52, 4106-4112.
29. Powles, T.J., Hardy, J.R. and Ashley, S.E. (1989) A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br. J. Cancer, 60, 126-131.
30. Powles, T.J., Tilner, C.R. and Jones, A.L. (1990) Prevention of breast cancer with tamoxifen update on the Royal Marsden Hospital Pilot Program. Eur. J. Cancer, 26, 680-684.
31. Rivera, E.S., Andrade, N., Martin, G., Melito, G., Cricco, G., Mohamad, N., Davio, C., Caro, R. and Bergoc, R.M. (1994) Induction of mammary tumors in rat by intraperitoneal injection of NMU: histopathology and estral cycle influence. Cancer Lett., 86, 223-228.
32. Russo, J., Russo, I.H., Rogers, A.E., van Zwieten, M.J. and Gusterson, B. (1990) Tumors of the mammary glands. In: Pathology of Tumors in Laboratory Animals. Vol. 1. Tumors of the Rat (IARC, Scientific Publication No. 99). Editor: V.S. Turusov. International Agency for Research on Cancer, Lyon, France.
33. Robinson, S.P. and Jordan, V.C. (1988) Antitumor actions of toremifene in the 7,12-dimethyl-benzoanthracene (DMBA)-induced rat mammary tumor model. Eur. J. Cancer Clin. Oncol., 26, 1817-1821.
34. Sarcaria, J.N., Gibson, D., Jordan, V., Fowler, J., Lindstrom, M. and Mulcahy, T. (1993) Tamoxifen-induced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. Cancer Res., 53, 4413-4417.
35. Turkot-Lemay, L. and Kelly, P. (1980) Characterization of estradiol, progesterone and prolactin receptors in nitrosomethylurea-induced mammary tumors and effect of anti-estrogen treatment on the development and growth of these tumors. Cancer Res., 40, 3232-3240.
36. Vignon, F., Bourton, M. and Rochefort, H. (1987) Anti-estrogen inhibits the mitogenic effect of growth factors on breast cancer cells in the total absence of estradiol. Biochem. Biophys. Res. Commun., 146, 1502-1508.